Feedback / Questions
AK006 - Allakos
https://www.globenewswire.com/news-release/2024/05/28/2888894/0/en/Allakos-Announces-First-Patient-Dosed-in-Phase-1-Trial-of-AK006-in-Chronic-Spontaneous-Urticaria.html
May 28, 2024
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Prev
Next